Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. Watch these crucial price levels.
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Moderna Inc (NASDAQ:MRNA) stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro. On ...
Moderna shares soared Tuesday as investors ... but also sits below overbought levels, giving the stock sufficient room to test higher prices. Let’s identify three key overhead areas where ...
Moderna’s (Nasdaq: MRNA) stock price fell 17% Monday, with shares priced at $35.15 apiece and a market cap of $13.53 billion. That's down ten-fold from its peak market value in September 2021.
If we assume Moderna only hits the low end of its 2025 revenue forecast, the stock trades at roughly 9 times forward sales. That's well above the 7.2 price-to-sales ratio for the biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback